- Trials with a EudraCT protocol (33)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
33 result(s) found for: Paired comparison.
Displaying page 1 of 2.
EudraCT Number: 2013-003542-17 | Sponsor Protocol Number: CU-LATER | Start Date*: 2014-06-11 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with r... | ||
Medical condition: Chronic Spontaneous Urticaria | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2015-002034-47 | Sponsor Protocol Number: AF219-014 | Start Date*: 2015-10-12 |
Sponsor Name:Afferent Pharmaceuticals, Inc. | ||
Full Title: A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects | ||
Medical condition: Chronic cough | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004319-37 | Sponsor Protocol Number: 001.4 | Start Date*: 2019-06-19 | |||||||||||
Sponsor Name:Medical University of Vienna, Department of Surgery | |||||||||||||
Full Title: A prospective, randomised, single-blind explorative study to investigate the efficacy and safety of fat graft enrichment with autologous platelet lysate in female breast augmentation | |||||||||||||
Medical condition: Fat grafting e.g. to the breast to restore small tissue defects is a very common and safe surgical procedure. Its main success among other is depended on the survival rate of the transferred fat ti... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013262-84 | Sponsor Protocol Number: V00400SB201 | Start Date*: 2009-10-28 | |||||||||||
Sponsor Name:PIERRE FABRE DERMATOLOGIE | |||||||||||||
Full Title: A randomised, controlled, multidose, multicentre, adaptive phase II/III study in infants with proliferating infantile hemangiomas requiring systemic therapy to compare four regimens of propranolol ... | |||||||||||||
Medical condition: Proliferating Infantile Hemangioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed) HU (Completed) LT (Completed) CZ (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003471-39 | Sponsor Protocol Number: Miltefosin bei AD | Start Date*: 2007-08-24 |
Sponsor Name:Prof. Dr. med. Margitta Worm | ||
Full Title: Explorative analysis of topical miltefosine application in adult patients with atopic dermatitis. | ||
Medical condition: Atopic Dermatitis (AD) is a chronic, inflammatory skin disease combined with intense itching. Beside the existing genetic background, various environmental factors impact the pathophysiology. Topic... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004746-33 | Sponsor Protocol Number: 310123 | Start Date*: 2008-09-17 | |||||||||||
Sponsor Name:Bayer HealthCare Pharmaceuticals INC | |||||||||||||
Full Title: A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist®) in patients referred for contrast-enhanced MRI of the cent... | |||||||||||||
Medical condition: Male and female patients of any ethnic group who are referred for a contrast-enhanced MRI of the CNS based on current clinical symptoms or results of a previous imaging procedure. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001286-17 | Sponsor Protocol Number: REMIT0401 | Start Date*: 2006-09-08 | |||||||||||
Sponsor Name:Fundación Española de Esclerosis Múltiple (FEDEM) | |||||||||||||
Full Title: Exploratory trial to evaluate the risk-benefit ratio of the use of mitoxantrone in patients under treatment with high dose interferon-beta-1a for relapsing-remitting or relapsing secondary progresi... | |||||||||||||
Medical condition: Relapsing-remitting or relapsing secondary progressive multiple sclerosis with high activity | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001680-33 | Sponsor Protocol Number: MH-130 | Start Date*: 2006-06-23 | |||||||||||
Sponsor Name:BRACCO IMAGING | |||||||||||||
Full Title: Phase IV, Double-blind, Multi-center, Randomized, Cross-over Study to Compare 0.10 mmol/kg of MultiHance R with 0.10 mmol/kg of Omniscan R in Magnetic Resonance Imaging MRI of the Brain | |||||||||||||
Medical condition: patients sent to the sites with a request for assessment/diagnoses of certain/suspected brain neoplasms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004837-34 | Sponsor Protocol Number: STH17245 | Start Date*: 2014-08-20 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Lung HeXeRT: Advanced proton, hyperpolarised 3helium and 129xenon magnetic resonance imaging for lung cancer radiotherapy planning and evaluation | |||||||||||||
Medical condition: Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000995-41 | Sponsor Protocol Number: FBX104114 | Start Date*: 2007-02-20 |
Sponsor Name:GlaxoSmithKline R&D | ||
Full Title: A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibros... | ||
Medical condition: Chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-005022-10 | Sponsor Protocol Number: SYN-1748-MAL-0030-I | Start Date*: 2018-02-13 | ||||||||||||||||
Sponsor Name:Technische Universität München, Fakultät für Medizin | ||||||||||||||||||
Full Title: Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | ||||||||||||||||||
Medical condition: Noonan Syndrom and Neurofibromatosis Type 1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005581-39 | Sponsor Protocol Number: CL3-12911-025 | Start Date*: 2007-04-02 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A double-blind, multicenter, international randomised study to assess the effects of 6 months or 12 months administration of 2g per day of strontium ranelate versus alendronate 70mg per week on bo... | |||||||||||||
Medical condition: Treatment of postmenopausal Osteoporosis to reduce the risk of hip and vertebral fractures | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) HU (Completed) NL (Completed) CZ (Completed) IT (Completed) DK (Completed) EE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002573-35 | Sponsor Protocol Number: OZM-058 | Start Date*: 2019-08-30 | |||||||||||
Sponsor Name:University Health Network, Toronto | |||||||||||||
Full Title: A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer. | |||||||||||||
Medical condition: Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003706-27 | Sponsor Protocol Number: D8530C00002 | Start Date*: 2020-02-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative B... | |||||||||||||
Medical condition: Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) DE (Completed) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002809-48 | Sponsor Protocol Number: CRO782 | Start Date*: 2013-04-17 | |||||||||||
Sponsor Name:Imperial College London and Imperial College Healthcare NHS Trust | |||||||||||||
Full Title: Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure and a left ventricular assist device | |||||||||||||
Medical condition: Advanced heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001487-37 | Sponsor Protocol Number: 190342-032D | Start Date*: 2008-11-05 |
Sponsor Name:Allergan Limited | ||
Full Title: A Multicenter, Masked, Randomized, Sham-controlled, Paired-eye Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal Structure and Visual Function of Br... | ||
Medical condition: Geographic Atrophy from Age-related Macular Degeneration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) PT (Completed) IT (Completed) GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-002157-64 | Sponsor Protocol Number: | Start Date*: 2012-03-07 |
Sponsor Name:Common Services Agency | ||
Full Title: ARomatase Inhibition plus minus SaracaTinib as Advanced breast CAncer Therapy: a randomised phase II study of aromatase inhibition plus/minus the src-inhibitor AZD0530 in post-menopausal women with... | ||
Medical condition: Advanced breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003162-42 | Sponsor Protocol Number: M/37779/21 | Start Date*: 2005-10-21 |
Sponsor Name:Almirall Prodesfarma S.A. | ||
Full Title: A double-blind, randomized, parallel, multicenter, vehicle-controlled, left/right paired comparison to study the efficacy, safety and tolerability of 1% LAS 37779 cream administered once and twice ... | ||
Medical condition: patients with mild to moderate chronic plaque psoriasis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004976-35 | Sponsor Protocol Number: CVT 5131 | Start Date*: 2005-04-01 | |||||||||||
Sponsor Name:CV Therapeutics, Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind Study of Intravenous CVT 3146 vs. Adenoscan® in Patients Undergoing Stress Myocardial Perfusion Imaging | |||||||||||||
Medical condition: Myocardial Ischaemia (diagnosis of ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000946-37 | Sponsor Protocol Number: 2019-06 | Start Date*: 2020-11-30 | |||||||||||
Sponsor Name:Assistance Publique-Hôpitaux de Marseille | |||||||||||||
Full Title: Molecular imaging exploration of ocular angiogenic activity and evaluation of its relevance in the therapeutic follow-up of AMD patients. | |||||||||||||
Medical condition: Age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
